Stock Taper
Anteris Technologies develops innovative medical devices, including the DurAVR transcatheter heart valve, ADAPT anti-calcification tissue, and ComASUR delivery system, to improve treatment for aortic stenosis and related cardiac conditions.

DurAVR™ THV is a biomimetic, single-piece transcatheter aortic valve designed to treat severe aortic stenosis, currently in global pivotal trials and serving as Anteris' flagship product.
| Map | REGION | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | UNITED STATES | $420K | $301K ▼ | $484K ▲ | $995K ▲ |
![]() | AUSTRALIA | $9K | $8K ▼ | $10K ▲ | $14K ▲ |
![]() | GERMANY | — | $1K | — | — |
Overall rating: C
| PEER | PRICE | |
|---|---|---|
ANIK | $21.10 | COMPARE |
NKTX | $2.76 | COMPARE |
LUCD | $0.99 | COMPARE |
MXCT | $1.22 | COMPARE |
LNSR | $8.30 | COMPARE |
OWLT | $4.99 | COMPARE |
ARAY | $0.27 | COMPARE |